Research
Seaport Therapeutics to present on Thursday, December 11, 2025 at 10:00 AM EST.
Seaport Therapeutics presents at Stifel 2025 Healthcare Conference
Seaport Therapeutics presents at Oppenheimer Private Life Sciences Company Showcase 2025
An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans
Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport
Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity
Development and Application of Physiologically Based Modeling of Lymphatic Absorption and Disposition of Allopregnanolone to Support of Model-Informed Drug Development of Lymphatic Glyph Prodrugs
Population Pharmacokinetic Modeling of Oral GlyphAllo in Healthy Volunteers Strengthens Evidence for Lymphatic Absorption of Glyph Prodrugs
GlyphAgo demonstrated 6.8-fold increased bioavailability and 10-fold reduced variability versus unmodified agomelatine in healthy volunteers at doses projected to mitigate liver exposure
